$950 Million is the total value of VR Adviser, LLC's 37 reported holdings in Q3 2023. The portfolio turnover from Q2 2023 to Q3 2023 was 50.0% .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
GHRS | Sell | GH RESEARCH PLCordinary shares | $27,578,456 | -33.9% | 2,744,125 | -22.0% | 2.90% | -56.5% |
AMAM | Sell | AMBRX BIOPHARMA INCsponsored ads | $23,805,000 | -41.8% | 2,070,000 | -16.7% | 2.51% | -61.7% |
AGLE | Sell | AEGLEA BIOTHERAPEUTICS INC | $3,614,167 | +26.5% | 295,034 | -95.3% | 0.38% | -16.8% |
Exit | AVALO THERAPEUTICS INC | $0 | – | -1,250,000 | -100.0% | -0.07% | – | |
BDTX | Exit | BLACK DIAMOND THERAPEUTICS I | $0 | – | -353,629 | -100.0% | -0.29% | – |
Exit | THESEUS PHARMACEUTICALS INC | $0 | – | -770,000 | -100.0% | -1.15% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-11-14
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
ACLARIS THERAPEUTICS INC | 12 | Q3 2023 | 12.7% |
VIRIDIAN THERAPEUTICS INC | 12 | Q3 2023 | 13.4% |
COGENT BIOSCIENCES INC | 12 | Q3 2023 | 10.3% |
RELMADA THERAPEUTICS INC | 11 | Q3 2022 | 9.9% |
GH RESEARCH PLC | 10 | Q3 2023 | 6.7% |
ALTIMMUNE INC | 9 | Q3 2022 | 11.6% |
MARINUS PHARMACEUTICALS INC | 9 | Q4 2022 | 5.7% |
CELLDEX THERAPEUTICS INC | 9 | Q3 2022 | 7.6% |
AFFIMED N V | 8 | Q3 2023 | 1.1% |
INSTIL BIO INC | 7 | Q3 2022 | 18.7% |
View VR Adviser, LLC's complete holdings history.
Latest filings
Type | Filed |
---|---|
13F-HR | 2024-05-15 |
13F-HR | 2024-02-14 |
13F-HR | 2023-11-14 |
13F-HR | 2023-08-11 |
13F-HR/A | 2023-05-15 |
13F-HR/A | 2023-05-15 |
13F-HR/A | 2023-05-15 |
13F-HR | 2023-05-15 |
13F-HR | 2023-02-14 |
13F-HR | 2022-11-14 |
View VR Adviser, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.